Moderately to Severely Active Ulcerative Colitis Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Moderately to Severely Active Ulcerative Colitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche100 enrolled4 locationsNCT07158242
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled196 locationsNCT06588855
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis

Adult Patients With Moderately to Severely Active Ulcerative Colitis
Guangdong Hengrui Pharmaceutical Co., Ltd20 enrolled1 locationNCT07232576
Recruiting
Phase 2

A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease

Adult Patients With Moderately to Severely Active Ulcerative Colitis
Shandong Suncadia Medicine Co., Ltd.66 enrolled1 locationNCT07229950
Recruiting
Phase 3

Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Takeda402 enrolled36 locationsNCT03221036
Recruiting
Phase 2

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

UC - Ulcerative ColitisModerately to Severely Active Ulcerative Colitis
InventisBio Co., Ltd120 enrolled1 locationNCT07035041